Earnings Report Digest

$NVS Novartis AG has released its Q4 2024 earnings report, showcasing solid growth. Key metrics: EPS of $1.98 (+33%) and revenue of $13.15B (+15.14% Y/Y). Risks include anticipated generic competition impacting sales and the potential for revenue fluctuations. Highlights include a 38.7% core operating margin, with the company projecting mid-single-digit growth for 2025. Future opportunities lie in a strong pipeline and continued brand performance, including Entresto and Kisqali. For detailed insights, check http://valueverge.com/NVS.

$ABBV released its Q4 2024 earnings, revealing adjusted EPS of $2.16, missing estimates by $0.10, but total revenues of $15.10B surpassed expectations, showing a 6.1% growth. Risks include ongoing biosimilar pressures for Humira, while highlights include strong performances from Skyrizi and Rinvoq, contributing to a 22% revenue boost. Future outlook suggests robust mid-single-digit revenue growth for 2025 with anticipated increases from their ex-Humira platform. For more details, check http://valueverge.com/ABBV.

$XOM has released its Q4 2024 earnings report, showing an EPS of $1.67, beating estimates by $0.12, while revenue of $83.43B fell short by $3.77B, highlighting some risks in overall financial health. Highlights include strong cash flow at $55B and an industry-leading return on capital employed of 13%.

Trending stocks, Jan 31, 2025

$AAPL has released its Q4 Fiscal Year 2024 earnings, reporting a revenue of $94.9 billion, marking a 6% year-over-year increase. Key highlights include a record iPhone revenue of $46.2 billion, and an all-time high in Services revenue at $25 billion. Risks include a one-time tax charge impacting net income and future uncertainties surrounding the macroeconomic landscape.

$V has released its fiscal Q4 & full-year 2024 earnings. Key stats show $9.6B in revenue (+12% YoY) and EPS at $2.71 (+16%). Risks include regulatory scrutiny from the DOJ lawsuit and weakness in Asia-Pacific's volume growth.

$MA has released its Q4 and full-year 2024 earnings, showing a solid performance with net revenues up 16% and adjusted net income increasing by 19% year-over-year. Key highlights include robust consumer spending and a diversified portfolio driving growth across various segments. Notably, the company continues to expand its partnerships and invest in innovative solutions, addressing the growing demand for digital payments while navigating risks like foreign exchange volatility and acquisition costs.

$TMO is set to release its Q4 earnings report, showcasing solid revenue growth of 5% year-over-year to $11.4 billion and adjusted EPS rising 8% to $6.10, reflecting strong operational performance. Key highlights include 23.9% adjusted operating margins and a positive trajectory across all business segments. Risks remain with continued fallout from COVID-related revenue runoff. As they look to 2025, they aim for revenue between $43.5 billion and $44 billion with EPS growth of 6% to 8%. Check details at http://valueverge.com/TMO.

$CAT has released its earnings report for Q4 2024, showing adjusted profit per share at $5.14, down 2% year-over-year, with services revenue growing to a record $24 billion. Despite a 5% decrease in total sales to $16.2 billion, the backlog rose to $30 billion . For 2025, a slight drop in sales is anticipated, but services are expected to grow . Risks include lower sales volumes and potential pricing pressures. Highlights include solid cash flow of $9.4 billion . For more details, visit http://valueverge.com/CAT.

$CMCSA has released its latest earnings report, highlighting record revenue of $124 billion and adjusted EBITDA of $38 billion for 2024. Key growth in wireless and convergence revenue was noted, with adjusted EPS rising by 9%. However, the broadband segment faced challenges, losing 139K subscribers in Q4 due to intense competition.